A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease

Journal of Medicinal Chemistry

Volumn 59, Issue 7, 2016, Pages 3098-3111

  Kalindjian, S Barret ^a   Kadnur, Sanjay V ^b   Hewson, Christopher A ^a   Venkateshappa, Chandregowda ^b   Juluri, Suresh ^b   Kristam, Rajendra ^b   Kulkarni, Bheemashankar ^b   Mohammed, Zainuddin ^b   Saxena, Rohit ^b   Viswanadhan, Vellarkad N ^b   Aiyar, Jayashree ^b   McVey, Donna ^a  

^a Keaton House   (United Kingdom)

^b JUBILANT BIOSYS LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 7 CHLORO 1,3 DIOXOISOINDOLIN 2 YL]METHYL]PYRIDINE 1 OXIDE; 3 [4 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 7 CHLORO 1,3 DIOXOISOINDOLIN 2 YL] 2 METHOXYPYRIDINE 1 OXIDE; 3 [4 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 7 CHLORO 1,3 DIOXOISOINDOLIN 2 YL] 2 METHYL PYRIDINE 1 OXIDE; 3 [4 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 7 CHLORO 1,3 DIOXOISOINDOLIN 2 YL] 2 METHYLPYRIDINE 1 OXIDE; 3 [4 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 7 CHLORO 1,3 DIOXOISOINDOLIN 2 YL]PYRIDINE 1 OXIDE; 3 [[4 [4 (TERT BUTYL)PHENYLSULFONAMIDO] 7 CHLORO 1,3 DIOXOISOINDOLIN 2 YL]METHYL]PYRIDINE 1 OXIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (2 CYANO 5 METHYLPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (2 FLUOROPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (2 METHOXYPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (2 METHYLPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (2,5 DIMETHYLPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (4 ETHOXYPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (4 METHOXYPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (4 METHYLPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (5 CYANOPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (5 ETHOXYPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (5 METHOXYPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (5 METHYLPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (6 FLUOROPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (6 METHOXYPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (6 METHYLPYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (PYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 (PYRIDIN 3 YLMETHYL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CHLORO 2 [2 (PYRIDIN 3 YL)ETHYL] 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 CYANO 1,3 DIOXO 2 (PYRIDIN 3 YLMETHYL)ISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 METHYL 2 (PYRIDIN 3 YL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; 4 (TERT BUTYL) N [7 METHYL 2 (PYRIDIN 3 YLMETHYL) 1,3 DIOXOISOINDOLIN 4 YL]BENZENESULFONAMIDE; CHEMOKINE RECEPTOR CCR9 ANTAGONIST; ISOINDOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CC CHEMOKINE RECEPTOR 9; CCX282-B; CHEMOKINE RECEPTOR CCR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRECLINICAL STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; CHEMOTAXIS; COLITIS; DISEASE MODEL; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY TECHNIQUES, SYNTHETIC; CHEMOTAXIS; COLITIS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; ISOINDOLES; MALE; MICE, INBRED C57BL; RECEPTORS, CCR; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84966282805     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01840     Document Type: Article

References (30)

1. Bouma, G.; Strober, W. The immunological and genetic basis of inflammatory bowel disease Nat. Rev. Immunol. 2003, 3, 521-533 10.1038/nri1132
2. Vinader, V.; Afarinkia, K. A beginner's guide to chemokines Future Med. Chem. 2012, 4, 845-852 10.4155/fmc.12.49
3. Zabel, B. A.; Agace, W. W.; Campbell, J. J.; Heath, H. M.; Parent, D.; Roberts, A. I.; Ebert, E. C.; Kassam, N.; Qin, S.; Zovko, M.; La Rosa, G. J.; Yang, L. L.; Soler, D.; Butcher, E. C.; Ponath, P. D.; Parker, C. M.; Andrew, D. P. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine mediated chemotaxis J. Exp. Med. 1999, 190, 1241-1256 10.1084/jem.190.9.1241
4. Zaballos, A.; Gutiérrez, J.; Varona, R.; Ardavín, C.; Márquez, G. Cutting edge: Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine CCL25 J. Immunol. 1999, 162, 5671-5675
5. Kunkel, E. J.; Campbell, J. J.; Haraldsen, G.; Pan, J.; Boisvert, J.; Roberts, A. I.; Ebert, E. C.; Vierra, M. A.; Goodman, S. B.; Genovese, M. C.; Wardlaw, A. J.; Greenberg, H. B.; Parker, C. M.; Butcher, E. C.; Andrew, D. P.; Agace, W. W. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of the tissue-specific chemokines as an organizing principle in regional immunity J. Exp. Med. 2000, 192 (5) 761-768 10.1084/jem.192.5.761
6. Papadakis, K. A.; Prehn, J.; Moreno, S. T.; Cheng, L.; Kouroumalis, E. A.; Deem, R.; Breaverman, T.; Ponath, P. D.; Andrew, D. P.; Green, P. H.; Hodge, M. R.; Binder, S. W.; Targan, S. R. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease Gastroenterology 2001, 121, 246-254 10.1053/gast.2001.27154
7. Rivera-Nieves, J.; Ho, J.; Bamias, G.; Ivashkina, N.; Ley, K.; Oppermann, M.; Cominelli, F. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis Gastroenterology 2006, 131, 1518-1529 10.1053/j.gastro.2006.08.031
8. Walters, M. J.; Wang, Y.; Lai, N.; Baumgart, T.; Zhao, B. N.; Dairaghi, D. J.; Bekker, P.; Ertl, L. S.; Penfold, M. E. T.; Jaen, J. C.; Keshav, S.; Wendt, E.; Pennell, A.; Ungashe, S.; Wei, Z.; Wright, J. K.; Schall, T. J. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for the treatment of inflammatory bowel disease J. Pharmacol. Exp. Ther. 2010, 335, 61-69 10.1124/jpet.110.169714
9. Carballido Herrera, J. M.; Jaksche, H.; Lehr, P.; Werner, G.; Winiski, A. Inhibitors of CCR9 activity. Patent WO 2007/071441, June 28, 2007.
10. Ungashe, S.; Wei, Z.; Wright, J. J.; Pennell, A. Aryl sulfonamides. Patent WO 2004/046092, July 15, 2004.
11. Charvat, T. T.; Hu, C.; Melikian, A.; Novack, A.; Pennell, A. M. K.; Powers, J.; Punna, S.; Sullivan, E. J.; Thomas, W. D.; Ungashe, S.; Zhang, P. N-(2-(Hetaryl)aryl)arylsulfonamides and N-(2-(Hetaryl)hetaryl)arylsulfonamides. Patent WO 2009/038847, March 26, 2009.
12. Ugashe, S.; Wei, Z.; Wright, J. J.; Pennell, A. Aryl sulfonamides. US Patent US 2004/0171654, September 2, 2004.
13. Fleming, P.; Harriman, G. C. B.; Shi, Z.; Chen, S. CCR9 inhibitors and methods of use thereof. Patent WO2003/099773, December 4, 2003.
14. Anderson, E. C.; Biediger, R. J.; Chen, J.; Dupre, B.; Lory, P.; Market, R. V.; Monk, K. A.; Savage, M. M.; Tennyson, R.; Young, B. M. Modulators of CCR9 receptor and methods of use thereof. US Patent US 2010/0029753, February 4, 2010.
15. Koenecke, C.; Förster, R. CCR9 and inflammatory bowel disease Expert Opin. Ther. Targets 2009, 13, 297-306 10.1517/14728220902762928
16. Proudfoot, A. E.; Power, C. A.; Schwarz, M. K. Anti-chemokine small molecule drugs: a promising future? Expert Opin. Invest. Drugs 2010, 19, 345-355 10.1517/13543780903535867
17. Keshav, S.; Vaňásek, T.; Niv, Y.; Petryka, R.; Howaldt, S.; Bafutto, M.; Rácz, I.; Hetzel, D.; Nielsen, O. H.; Vermeire, S.; Reinisch, W.; Karlén, P.; Schreiber, S.; Schall, T. J.; Bekker, P. Prospective randomized oral-therapy evaluation in Crohn's disease trial-1 PROTECT-1 study group PLoS One 2013, 8 (3) e60094 10.1371/journal.pone.0060094
18. Wendt, E.; Keshav, S. CCR9 antagonism: potential in the treatment of inflammatory bowel disease Clin. Exp. Gastroenterol. 2015, 8, 119-130 10.2147/CEG.S48305
19. Feagan, B. G.; Sandborn, W. J.; D'Haens, G.; Lee, S. D.; Allez, M.; Fedorak, R. N.; Seidler, U.; Vermeire, S.; Lawrance, I. C.; Maroney, A. C.; Jurgensen, C. H.; Heath, A.; Chang, D. J. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease Aliment. Pharmacol. Ther. 2015, 42, 1170-1181 10.1111/apt.13398
20. Zhang, J.; Romero, J.; Chan, A.; Goss, J.; Stucka, S.; Cross, J.; Chamberlain, B.; Varoglu, M.; Chandonnet, H.; Ryan, D.; Lippa, B. Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease Bioorg. Med. Chem. Lett. 2015, 25, 3661-3664 10.1016/j.bmcl.2015.06.046
21. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists J. Med. Chem. 1988, 31, 2235-2246 10.1021/jm00120a002
22. Yu, C. R.; Peden, K. W.; Zaitseva, M. B.; Golding, H.; Farber, J. M. CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand J. Immunol. 2000, 164, 1293-1305 10.4049/jimmunol.164.3.1293
23. Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J. Basic local alignment search tool J. Mol. Biol. 1990, 215, 403-410 10.1016/S0022-2836(05)80360-2
24. Jaroszewski, L.; Rychlewski, L.; Li, Z.; Li, W.; Godzik, A. FFAS03: a server for profile-profile sequence alignments Nucleic Acids Res. 2005, 33, W284-W288 10.1093/nar/gki418
25. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex Science 2013, 341, 1387-1390 10.1126/science.1241475
26. Pei, J.; Kim, B. H.; Grishin, N. V. PROMALS3D: a tool for multiple sequence and structure alignment Nucleic Acids Res. 2008, 36, 2295-2300 10.1093/nar/gkn072
27. Jacobson, M. P.; Kaminski, G. A.; Friesner, R. A.; Rapp, C. S. Force field validation using protein side chain prediction J. Phys. Chem. B 2002, 106, 11673-11680 10.1021/jp021564n
28. Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.; Friesner, R. A. A Hierarchical approach to all-atom protein loop prediction Proteins: Struct., Funct., Genet. 2004, 55, 351-367 10.1002/prot.10613
29. Prime, version 3.8, Schrödinger, LLC, New York, NY, 2014.
30. Zhao, H.; Zhang, H.; Wu, H.; Li, H.; Liu, L.; Guo, J.; Li, C.; Shih, D.; Zhang, X. Protective role of 1,25(OH)2vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice BMC Gastroenterol. 2012, 12, 57 10.1186/1471-230X-12-57